HPH III Investments LP, a private equity firm focused on the healthcare industry, has acquired Allergy Research Group LLC, a leading provider of allergy and immunology products. The transaction closed on July 7, 2023.
| Acquirer | Target | Deal Value | Type | Close Date |
|---|---|---|---|---|
| HPH III Investments LP (US) | Allergy Research Group LLC (US) | Undisclosed | Acquisition | July 7, 2023 |
The acquisition aims to expand HPH III's presence in the fast-growing healthcare practitioner channel. WM Partners, an affiliate of HPH III and a leading private equity firm with expertise in operational improvement, will leverage its resources to support Allergy Research Group’s continued growth.
Strategic Rationale
HPH III Investments LP sees significant potential for expansion within the healthcare practitioner market. By acquiring Allergy Research Group, HPH III aims to strengthen its portfolio with a company that has a strong reputation in allergy and immunology products. WM Partners’ operational expertise will be instrumental in driving further development and innovation.
Financial Context
The deal’s financial terms were not disclosed by the parties involved, making it challenging to assess the precise valuation or synergies expected from this transaction. However, HPH III is known for strategic acquisitions that align with long-term growth objectives in the healthcare sector.
Advisors
Rothschild & Co acted as financial advisor to Allergy Research Group on the deal while King & Spalding provided legal counsel to HPH III Investments LP. No other advisors were disclosed by either party involved.
Outlook
The acquisition is expected to enhance Allergy Research Group’s market position and expand its distribution reach, enabling it to better serve healthcare practitioners and patients in need of specialized allergy care products.